Clinical Evidence

Results across our clinical development program demonstrate the safety and impact of Targeted Lung Denervation (TLD) using the dNerva® Lung Denervation System. Detailed information regarding Nuvaira clinical studies can also be found at


dNerva® Clinical Development Program


Over 500 patients have been treated in Nuvaira’s clinical studies.
Find out more about each of the studies in Nuvaira’s clinical development program.

Published in the International Journal of Chronic Obstructive Pulmonary Disease, November 20202

The clinical impact of TLD is durable, as it is found to reduce the risk of serious COPD adverse events over 2 years with stabilized lung function. The reduction of severe COPD exacerbations has the potential to improve long-term clinical outcomes and reduce healthcare costs.

AIRFLOW-2 Study Conclusions

Robust study design

Positive Safety Profile

TLD demonstrated a significantly lower risk of hospitalized COPD exacerbations

Lung function and quality of life remained stable over 2 years

Published in Respiratory Research, February 202121

TLD in COPD patients demonstrated a positive safety profile out to 3 years, with no late-onset serious adverse events related to denervation therapy. Clinical stability in lung function, quality of life, and exacerbations were observed in TLD treated patients over 3 years of follow up.

Results: Observed Clinical Stability after Three Years21,22

Stable Quality of Life

Stable COPD Exacerbation Rates

Stable Lung Function

1:1 Randomized, Double-Blind, Sham-Controlled FDA Pivotal Trial

Primary Endpoint:

Comparison of the probability of subjects having a moderate or severe exacerbation between the treatment arm and the sham control arm at one year

464 patients treated

Multicenter (USA, Europe)


dNerva Targeted Lung Denervation Bibliography

dNerva Targeted Lung Denervation Mechanism of Action Bibliography

COPD Exacerbations are the Problem.
Be a Part of the Solution.

The AIRFLOW-3 Clinical Trial is the first interventional COPD device trial targeting exacerbation risk reduction in patients on optimal drug therapy.